Oral Semaglutide
OASIS 1
Novo Nordisk · Phase 3 · Completed · Enrollment 667
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Oral semaglutide | 173 participants | 80 participants | 89 participants | n/r | 0 |
| Oral semaglutide placebo | 51 participants | 12 participants | 56 participants | n/r | 0 |
A count stays a count. This page does not turn a count into a percent.